London
· Delayed Price · Currency is GBP · Price in USD Agios Pharmaceuticals Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 488 |
| CEO | Brian Goff |
Contact Details
Address: 88 Sidney Street Cambridge, Delaware 02139 United States | |
| Phone | 617 649 8600 |
| Website | agios.com |
Stock Details
| Ticker Symbol | 0HB0 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00847X1046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Brian Goff | Chief Executive Officer |
| Cecilia Jones | Chief Financial Officer |
| Christopher J. Taylor | Head of Investor Relations |